Article

Parthenolide induces apoptosis in glioblastomas without affecting NF-kappaB.

Department of Biological Sciences, Western Michigan University, Kalamazoo 49008, USA.
Journal of Pharmacological Sciences (Impact Factor: 2.11). 03/2008; 106(2):318-20. DOI: 10.1254/jphs.SC0060164
Source: PubMed

ABSTRACT Parthenolide is a sesquiterpene lactone that has been isolated from Tanacetum parthenium (feverfew). Parthenolide has several biological activities including the induction of apoptosis and inhibition of NF-kappaB. Because of its activities against several tumor types and because it is relatively well tolerated, in clinical trial, parthenolide is an attractive compound for the treatment of brain tumors. However, there have been no reports concerning its ability to induce apoptosis in any brain tumor cell lines. In this report we demonstrate that treatment of glioblastoma cells with parthenolide resulted in rapid apoptosis through caspase 3/7 without a suppression of NF-kappaB activity.

0 Followers
 · 
40 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim:Receptor-interacting protein 3 (RIP3) is involved in tumor necrosis factor receptor signaling, and results in NF-κB-mediated prosurvival signaling and programmed cell death. The aim of this study was to determine whether overexpression of the RIP3 gene could sensitize human breast cancer cells to parthenolide in vitro.Methods:The expression of RIP3 mRNA in human breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-435 and T47D) was detected using RT-PCR. Both MDA-MB-231 and MCF-7 cells were transfected with RIP3 expression or blank vectors via lentivirus. Cell viability was measured with MTT assay; intracellular ROS level and cell apoptosis were analyzed using flow cytometry.Results:RIP3 mRNA expression was not detected in the four human breast cancer cell lines tested. However, the transfection induced higher levels of RIP3 protein in MCF-7 and MDA-MB-231 cells. Furthermore, overexpression of RIP3 decreased the IC50 values of parthenolide from 17.6 to 12.6 μmol/L in MCF-7 cells, and from 16.6 to 9.9 μmol/L in MDA-MB-231 cells. Moreover, overexpression of RIP3 significantly increased parthenolide-induced apoptosis and ROS accumulation in MCF-7 and MDA-MB-231 cells. Pretreatment with N-acetyl-cysteine abrogated the increased sensitivity of RIP3-transfected MCF-7 and MDA-MB-231 cells to parthenolide.Conclusion:Overexpression of RIP3 sensitizes MCF-7 and MDA-MB-231 breast cancer cells to parthenolide in vitro via intracellular ROS accumulation.
    Acta Pharmacologica Sinica 06/2014; 35(7). DOI:10.1038/aps.2014.31 · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is no highly effective chemotherapy for malignant gliomas to date. We found that dimethylaminomicheliolide (DMAMCL), a selective inhibitor of acute myeloid leukemia (AML) stem/progenitor cells, inhibited the growth of glioma cells. The distribution of DMAMCL in brain was analyzed by an ultraperformance liquid chromatography-mass spectrometry (UPLC-MS/MS) system. The anti-tumor evaluations of DMAMCL in vitro were performed by MTT, FACS and RT-PCR. In vivo, the mixture of C6 cells and matrigel was injected into caudatum, and the anti-tumor activity of DMAMCL was evaluated by tumor growth and rat survival. The toxicity of DMAMCL was evaluated by body weight, daily food intake, hematological or serum biochemical analyses, and histological appearance of tissues. The IC50 values of DMAMCL against the C6 and U-87MG cell lines in vitro were 27.18 ± 1.89 μM and 20.58 ± 1.61 μM, respectively. DAMMCL down-regulated the anti-apoptosis gene Bcl-2 and increased apoptosis in C6 and U-87MG cells in a dose-dependent manner. In a C6 rat tumor model, daily administration of DMAMCL for 21 days reduced the burden of C6 tumors by 60% to 88% compared to controls, and more than doubled the mean lifespan of tumor-bearing rats. Distribution analysis showed that the DMAMCL concentration was higher in the brain than in plasma. Evaluations for toxicity revealed that oral administration of DMAMCL at 200 or 300 mg/kg once a day for 21 days did not result in toxicity. These results suggest that DMAMCL is highly promising for the treatment of glioma.
    PLoS ONE 02/2015; 10(2):e0116202. DOI:10.1371/journal.pone.0116202 · 3.53 Impact Factor